Improving the Clinical Outcome of Unmanipulated Haploidentical Blood and Marrow Transplantation

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2015 Jun 4

PMID 26039202

Citations 6

Authors

Y-J Chang

X-J Huang

Affiliations

Soon will be listed here.

Abstract

Unmanipulated haploidentical blood and marrow transplantation (HBMT) has been one of the most applied haploidentical transplant protocol, which offers rapid immune recovery, desirable health-related quality of life and comparable survival rate with those who received HLA-identical sibling transplantation or HLA-matched unrelated donor transplantation. Compared with HLA-identical sibling recipients, HBMT recipients experienced a lower risk of late effects. The HBMT protocol also shows superior in treating pediatric hematological malignancies compared with umbilical cord blood transplantation and could be successfully used as a post-remission treatment algorithm for adults acute myeloid leukemia with unfavorable cytogenetics. Several approaches, including optimal dose investigation of anti-thymocyte globulin, selecting the best donor, and modified donor lymphocyte infusion, have been designed to improve transplant outcomes.

Citing Articles

Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.

Chang Y, Zhao X, Huang X Front Immunol. 2019; 10:2516.

PMID: 31749802 PMC: 6842971. DOI: 10.3389/fimmu.2019.02516.

[Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes].

Wang Y, Huang X Zhonghua Xue Ye Xue Za Zhi. 2017; 38(4):348-351.

PMID: 28468102 PMC: 7342714. DOI: 10.3760/cma.j.issn.0253-2727.2017.04.019.

[Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice].

Wang Y, Huang X Zhonghua Xue Ye Xue Za Zhi. 2016; 37(8):721-4.

PMID: 27587260 PMC: 7348534. DOI: 10.3760/cma.j.issn.0253-2727.2016.08.020.

[Strategy to improve clinical outcome of unmanipulated haploidentical stem cell transplantation without in vitro T cell depletion].

Chang Y, Huang X Zhonghua Xue Ye Xue Za Zhi. 2016; 37(8):716-20.

PMID: 27587259 PMC: 7348540. DOI: 10.3760/cma.j.issn.0253-2727.2016.08.019.

Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents.

Im H, Koh K, Seo J Blood Res. 2016; 51(1):8-16.

PMID: 27104186 PMC: 4828537. DOI: 10.5045/br.2016.51.1.8.

References

Chang Y, Huang X . Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant. 2014; 49(7):873-9. DOI: 10.1038/bmt.2014.19. View

Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B . Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014; 20(5):724-9. DOI: 10.1016/j.bbmt.2014.02.001. View

Yan C, Liu D, Xu L, Liu K, Zhao T, Wang Y . Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant. 2012; 26(6):868-76. DOI: 10.1111/j.1399-0012.2012.01618.x. View

Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland H . T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor.... J Clin Oncol. 2013; 31(10):1310-6. DOI: 10.1200/JCO.2012.44.3523. View

Chang Y, Zhao X, Huang X . Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 20(4):440-9. DOI: 10.1016/j.bbmt.2013.11.028. View

Mo X, Xu L, Liu D, Zhang X, Chen H, Chen Y . Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(5):777-83. DOI: 10.1016/j.bbmt.2013.01.026. View

Mo X, Xu L, Liu D, Chen Y, Han W, Zhang X . Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant. 2012; 47(9):1201-5. DOI: 10.1038/bmt.2011.250. View

Kong Y, Chang Y, Wang Y, Chen Y, Han W, Wang Y . Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(10):1465-73. DOI: 10.1016/j.bbmt.2013.07.014. View

Xu L, Liu K, Liu D, Han W, Chen H, Chen Y . A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012; 47(12):1507-12. DOI: 10.1038/bmt.2012.79. View

10.

Chang Y, Huang X . Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol. 2012; 19(6):454-61. DOI: 10.1097/MOH.0b013e3283582322. View

11.

Chang Y, Zhao X, Huo M, Xu L, Liu D, Liu K . Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2011; 32(2):268-80. DOI: 10.1007/s10875-011-9630-7. View

12.

Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R . Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2012; 121(5):849-57. DOI: 10.1182/blood-2012-08-453399. View

13.

Yan C, Liu D, Liu K, Xu L, Liu Y, Chen H . Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012; 119(14):3256-62. DOI: 10.1182/blood-2011-09-380386. View

14.

Mo X, Xu L, Liu D, Zhang X, Chen H, Chen Y . The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol. 2013; 88(6):497-502. DOI: 10.1002/ajh.23443. View

15.

Wang Y, Liu D, Liu K, Xu L, Zhang X, Han W . Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2012; 119(5):978-85. DOI: 10.1002/cncr.27761. View

16.

Huang X, Zhu H, Chang Y, Xu L, Liu D, Zhang X . The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012; 119(23):5584-90. DOI: 10.1182/blood-2011-11-389809. View

17.

Wang Y, Chang Y, Xu L, Liu K, Liu D, Zhang X . Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood. 2014; 124(6):843-50. DOI: 10.1182/blood-2014-03-563130. View

18.

Wang Y, Fu H, Liu D, Xu L, Zhang X, Chang Y . Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2013; 49(3):426-33. DOI: 10.1038/bmt.2013.191. View

19.

Wang Y, Liu D, Xu L, Liu K, Chen H, Zhang X . Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant. 2011; 47(8):1099-104. DOI: 10.1038/bmt.2011.213. View

20.

Chang Y, Huang X . Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?. Blood Rev. 2012; 27(1):55-62. DOI: 10.1016/j.blre.2012.11.002. View